

Camilla Evangelisti

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8871674/camilla-evangelisti-publications-by-year.pdf>
Version: 2024-04-11

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

79 papers	6,833 citations	37 h-index	82 g-index
82 ext. papers	7,507 ext. citations	6.3 avg, IF	5.18 L-index

#	Paper	IF	Citations
79	The wide and growing range of lamin B-related diseases: from laminopathies to cancer.. <i>Cellular and Molecular Life Sciences</i> , 2022 , 79, 126	10.3	3
78	GSK-3: a multifaceted player in acute leukemias. <i>Leukemia</i> , 2021 , 35, 1829-1842	10.7	4
77	Lamin A and Prelamin A Counteract Migration of Osteosarcoma Cells. <i>Cells</i> , 2020 , 9,	7.9	7
76	The Unfolded Protein Response: A Novel Therapeutic Target in Acute Leukemias. <i>Cancers</i> , 2020 , 12,	6.6	17
75	The Role Played by Wnt/ β Catenin Signaling Pathway in Acute Lymphoblastic Leukemia. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	18
74	Targeting Wnt/ β catenin and PI3K/Akt/mTOR pathways in T-cell acute lymphoblastic leukemia. <i>Journal of Cellular Physiology</i> , 2020 , 235, 5413-5428	7	23
73	B-ALL Complexity: Is Targeted Therapy Still A Valuable Approach for Pediatric Patients?. <i>Cancers</i> , 2020 , 12,	6.6	2
72	New advances in targeting aberrant signaling pathways in T-cell acute lymphoblastic leukemia. <i>Advances in Biological Regulation</i> , 2019 , 74, 100649	6.2	1
71	Advances in understanding the mechanisms of evasive and innate resistance to mTOR inhibition in cancer cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2019 , 1866, 1322-1337	4.9	10
70	The Cutting Edge: The Role of mTOR Signaling in Laminopathies. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	17
69	Elevated TGF β serum levels in Emery-Dreifuss Muscular Dystrophy: Implications for myocyte and tenocyte differentiation and fibrogenic processes. <i>Nucleus</i> , 2018 , 9, 292-304	3.9	15
68	Therapeutic targeting of CK2 in acute and chronic leukemias. <i>Leukemia</i> , 2018 , 32, 1-10	10.7	53
67	Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	24
66	Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia. <i>Journal of Cellular Physiology</i> , 2018 , 233, 1796-1811	7	22
65	PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines. <i>Oncotarget</i> , 2017 , 8, 23213-23227	3.3	10
64	Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: From biology to therapeutic targeting. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2016 , 1863, 449-463	4.9	81
63	Therapeutic potential of targeting sphingosine kinases and sphingosine 1-phosphate in hematological malignancies. <i>Leukemia</i> , 2016 , 30, 2142-2151	10.7	26

62	Potential therapeutic effects of the mTOR inhibitors for preventing ageing and progeria-related disorders. <i>British Journal of Clinical Pharmacology</i> , 2016 , 82, 1229-1244	3.8	37
61	Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway. <i>Journal of Hematology and Oncology</i> , 2016 , 9, 114	22.4	33
60	Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF- κ B. <i>Oncotarget</i> , 2016 , 7, 1323-40	3.3	30
59	The PI3K/Akt/mTOR Pathway 2016 , 128-135		1
58	Autophagy in acute leukemias: a double-edged sword with important therapeutic implications. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2015 , 1853, 14-26	4.9	58
57	Modulation of TGF β 2 levels by lamin A in U2-OS osteoblast-like cells: understanding the osteolytic process triggered by altered lamins. <i>Oncotarget</i> , 2015 , 6, 7424-37	3.3	24
56	Current treatment strategies for inhibiting mTOR in cancer. <i>Trends in Pharmacological Sciences</i> , 2015 , 36, 124-35	13.2	195
55	PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors. <i>Oncotarget</i> , 2015 , 6, 10399-414	3.3	29
54	Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling. <i>Leukemia</i> , 2014 , 28, 543-53	10.7	65
53	Targeting signaling pathways in T-cell acute lymphoblastic leukemia initiating cells. <i>Advances in Biological Regulation</i> , 2014 , 56, 6-21	6.2	31
52	Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia (review). <i>International Journal of Oncology</i> , 2014 , 45, 909-18	4.4	19
51	Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia. <i>Cell Cycle</i> , 2014 , 13, 2237-47	4.7	28
50	GSK-3 α key regulator of breast cancer drug resistance. <i>Cell Cycle</i> , 2014 , 13, 697-8	4.7	7
49	Assessment of the effect of sphingosine kinase inhibitors on apoptosis, unfolded protein response and autophagy of T-cell acute lymphoblastic leukemia cells; indications for novel therapeutics. <i>Oncotarget</i> , 2014 , 5, 7886-901	3.3	30
48	New Agents and Approaches for Targeting the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR Cell Survival Pathways 2013 , 331-372		1
47	Increased NGAL (Lnc2) expression after chemotherapeutic drug treatment. <i>Advances in Biological Regulation</i> , 2013 , 53, 146-55	6.2	14
46	Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia. <i>Expert Opinion on Therapeutic Targets</i> , 2013 , 17, 921-36	6.4	11
45	PI3K/AKT/mTORC1 and MEK/ERK signaling in T-cell acute lymphoblastic leukemia: new options for targeted therapy. <i>Advances in Biological Regulation</i> , 2012 , 52, 214-27	6.2	18

44	Targeting the liver kinase B1/AMP-activated protein kinase pathway as a therapeutic strategy for hematological malignancies. <i>Expert Opinion on Therapeutic Targets</i> , 2012 , 16, 729-42	6.4	34
43	The emerging multiple roles of nuclear Akt. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2012 , 1823, 2168-78	4.9	134
42	Targeting the cancer initiating cell: the ultimate target for cancer therapy. <i>Current Pharmaceutical Design</i> , 2012 , 18, 1784-95	3.3	36
41	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. <i>Oncotarget</i> , 2012 , 3, 1068-111	3.3	250
40	Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. <i>Oncotarget</i> , 2012 , 3, 954-87	3.3	214
39	DGKs degraded through the cytoplasmic ubiquitin-proteasome system under excitotoxic conditions, which causes neuronal apoptosis because of aberrant cell cycle reentry. <i>Cellular Signalling</i> , 2012 , 24, 1573-82	4.9	19
38	Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2012 , 26, 2336-42	10.7	63
37	Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. <i>Oncotarget</i> , 2012 , 3, 371-94	3.3	98
36	Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels. <i>Oncotarget</i> , 2012 , 3, 811-23	3.3	53
35	Advances in targeting signal transduction pathways. <i>Oncotarget</i> , 2012 , 3, 1505-21	3.3	39
34	Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway. <i>Leukemia</i> , 2011 , 25, 1064-79	10.7	156
33	Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. <i>Leukemia</i> , 2011 , 25, 1080-94	10.7	192
32	Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia. <i>Journal of Cellular Physiology</i> , 2011 , 226, 822-31	7	52
31	Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2011 , 25, 781-91	10.7	79
30	Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in cancer stem cells. <i>Current Medicinal Chemistry</i> , 2011 , 18, 2715-26	4.3	100
29	Nuclear phosphoinositides and their roles in cell biology and disease. <i>Critical Reviews in Biochemistry and Molecular Biology</i> , 2011 , 46, 436-57	8.7	28
28	Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. <i>Aging</i> , 2011 , 3, 192-222	5.6	437
27	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. <i>Oncotarget</i> , 2011 , 2, 135-64	3.3	456

26	Erucylphosphohomocholine, the first intravenously applicable alkylphosphocholine, is cytotoxic to acute myelogenous leukemia cells through JNK- and PP2A-dependent mechanisms. <i>Leukemia</i> , 2010 , 24, 687-98	10.7	31
25	Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. <i>Cancer Research</i> , 2010 , 70, 8097-107	10.1	136
24	The emerging role of the phosphatidylinositol 3-kinase/ akt/mammalian target of rapamycin signaling network in cancer stem cell biology. <i>Cancers</i> , 2010 , 2, 1576-96	6.6	32
23	Identification of a functional nuclear export sequence in diacylglycerol kinase-zeta. <i>Cell Cycle</i> , 2010 , 9, 384-8	4.7	24
22	The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2010 , 1803, 991-1002	4.9	97
21	The phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin signaling network and the control of normal myelopoiesis. <i>Histology and Histopathology</i> , 2010 , 25, 669-80	1.4	29
20	The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. <i>Oncotarget</i> , 2010 , 1, 89-103	3.3	200
19	TIS21/BTG2/PC3 and cyclin D1 are key determinants of nuclear diacylglycerol kinase-zeta-dependent cell cycle arrest. <i>Cellular Signalling</i> , 2009 , 21, 801-9	4.9	24
18	Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia. <i>Expert Opinion on Investigational Drugs</i> , 2009 , 18, 1333-49	5.9	94
17	Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance. <i>Leukemia</i> , 2008 , 22, 2080-90	10.7	59
16	Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells. <i>Leukemia</i> , 2008 , 22, 147-60	10.7	95
15	Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells. <i>Cancer Research</i> , 2008 , 68, 9394-403	10.1	76
14	Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy. <i>Advances in Enzyme Regulation</i> , 2008 , 48, 113-35		20
13	Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts. <i>Leukemia</i> , 2007 , 21, 427-38	10.7	151
12	The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion. <i>Leukemia</i> , 2007 , 21, 886-96	10.7	75
11	Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2007 , 1773, 1263-84	4.9	1532
10	Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance. <i>Advances in Enzyme Regulation</i> , 2007 , 47, 64-103		63
9	Nuclear diacylglycerol kinase-zeta is a negative regulator of cell cycle progression in C2C12 mouse myoblasts. <i>FASEB Journal</i> , 2007 , 21, 3297-307	0.9	40

8	Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside. <i>Current Medicinal Chemistry</i> , 2007 , 14, 2009-23	4.3	108
7	The Phosphoinositide 3-Kinase (PI3K)/AKT Signaling Pathway as a Therapeutic Target for the Treatment of Human Acute Myeloid Leukemia (AML). <i>Current Signal Transduction Therapy</i> , 2007 , 2, 246-256	0.8	2
6	Intranuclear 3-phosphoinositide metabolism and Akt signaling: new mechanisms for tumorigenesis and protection against apoptosis?. <i>Cellular Signalling</i> , 2006 , 18, 1101-7	4.9	112
5	Subnuclear localization and differentiation-dependent increased expression of DGK-zeta in C2C12 mouse myoblasts. <i>Journal of Cellular Physiology</i> , 2006 , 209, 370-8	7	29
4	Nuclear protein kinase C. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2006 , 1761, 542-51	5	60
3	Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. <i>Leukemia</i> , 2006 , 20, 911-28	10.7	269
2	Phosphoinositide 3-kinase/Akt inhibition increases arsenic trioxide-induced apoptosis of acute promyelocytic and T-cell leukaemias. <i>British Journal of Haematology</i> , 2005 , 130, 716-25	4.5	40
1	Nuclear inositol lipid metabolism: more than just second messenger generation?. <i>Journal of Cellular Biochemistry</i> , 2005 , 96, 285-92	4.7	30